Clinical trials: Major Depressive Disorder
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Late-life depression is characterized by both affective (mood) symptoms and cognitive deficits. There is currently no intervention that may provide consistent benefits to both mood and cognitive performance.
- Trial name
- NCT02816138
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Post Traumatic Stress Disorder, Schizophrenia
PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)
As in the general population, there is no clear standard of care within Veterans Affairs Medical Centers for treating posttraumatic stress disorder (PTSD) among individuals with severe mental illness (SMI).
- Conditions
- Post Traumatic Stress Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- PTSD/SMI (NCT01542229)
- Testing
- Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU), Treatment As Usual (TAU)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Riluzole Augmentation Pilot in Depression (RAPID) Trial
The investigators are doing a research study to find out if riluzole, when taken along with a standard antidepressant (sertraline) can help people with major depression.
- Trial name
- RAPID (NCT01703039)
- Testing
- Riluzole, Sertraline
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depression
Low Field Magnetic Stimulation for Treatment Resistant Depression
This is a double-blind, randomized, sham-controlled phase II study of the effects of Low Field Magnetic Stimulation (LFMS) on brain circuitry of adults with treatment-resistant Major Depressive Disorder (MDD).
- Trial name
- NCT01944644
- Testing
- Active Low Field Magnetic Stimulation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function
The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.
- Trial name
- iCBT (NCT01598922)
- Testing
- Internet Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mclean Hospital
Major Depression
Lexapro and Pramipexole and to Treat Major Depression
This study compares the effectiveness of the combination of antidepressants: Lexapro and Pramipexole, with the effectiveness of each antidepressant alone.
- Trial name
- NCT00086307
- Testing
- Pramipexole, Escitalopram
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder, Bipolar Depression
Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Mixed states in bipolar disorder have long been recognized. Over a century ago, it was argued that mixed states were the most common episodes in manic-depressive illness.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00490542
- Testing
- ziprasidone (Geodon)
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Tufts Medical Center
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
- Trial name
- NCT01034462
- Testing
- Levomilnacipran ER
- Where
- 23 sites in United States
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
The purpose of this study is to examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are…
- Trial name
- NCT02418195
- Testing
- ketamine
- Where
- United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Improving Therapeutic Learning in Depression: Proof of Concept
Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments.
- Trial name
- NCT02376257
- Testing
- 250 mg DCS, 100 mg Modafinil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston University Charles River Campus
Major Depressive Disorder
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous…
- Trial name
- NCT01436175
- Testing
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
- Where
- 212 sites in United States, Canada and 12 more
- Volunteers
- 1,570 people
- Sponsor
- Shire